• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    DCAT Week ’19

    Temperature-Controlled Logistics

    Reducing Pill Burden

    Nasal Drug Delivery

    AI in Pharma: Transforming Data into Drugs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Executive Moves: Daiichi Sankyo Co.

    Valitacell, Solentim Form Biologics Collaboration

    Werum, B-EN-G Enter Partnership

    Janssen, Morphic Ink Deal Worth up to $750M

    Catalent Appoints Tech Ops SVP
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Oakrum, Aucta Form Devt. & Mfg. Partnership

    Emergex Secures State-of-the-Art R&D Facility

    WuXi Biologics Completes EMA GMP Inspection

    Achillion Expands with Launch of PA Office

    ACG Capsules Expands in Brazil
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    ACG Capsules Expands in Brazil

    Catalent Receives P&G Award

    GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers

    Pelican BioThermal Opens New Network Location

    Reed-Lane Facility Tour
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Implementing AI in Drug Discovery

    Valitacell, Solentim Form Biologics Collaboration

    Werum, B-EN-G Enter Partnership

    Janssen, Morphic Ink Deal Worth up to $750M

    Merck to Acquire Immune Design for $300M
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    WuXi Biologics Completes EMA GMP Inspection

    Former FDA Senior Executives Join PAREXEL

    Top Global Pharma Company to Implement ValGenesis' VLMS

    WCG, Prudentia Enter Pharmacovigilance Alliance

    ValGenesis VLMS Chosen to Digitize Validation Process
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Vetter Pharma International GmbH

    Alcami

    Ajinomoto Bio-Pharma Services

    Aphena Pharma Solutions, Inc.

    Jubilant HollisterStier Contract Manufacturing & Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Ascendia Pharmaceuticals

    Aphena Pharma Solutions, Inc.

    Jubilant HollisterStier Contract Manufacturing & Services

    Emergent BioSolutions, Inc.

    Reed-Lane, Inc.
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Drugs as...Fashion?

    Fashion finds its way into pharma whether you like it or not

    Tesla models S, 3, and X = S3X-y, n
    Tesla models S, 3, and X = S3X-y, n'est pas?
    The number of products that now talk to you as the consumer is staggering. It
    The number of products that now talk to you as the consumer is staggering. It's created a differentiation challenge for Kate Spade and others. Courtesy: Kate Spade
    Related CONTENT
    • CEPI, Emergent and Profectus Enter Vaccine Mfg. pact
    • Contracting And Outsourcing Agenda
    • Catalent Invests $7.3M at Aprilia, Italy Facility
    • HPAPI Equipment Advances
    • Marrying Suppliers & Sponsors!
    Ben Locwin01.25.19
    I’ve been doing some work recently on the fashion within pharma: fashionable brand names, the fashion of typefaces, and how consumers clamor for—or reject the notion of—different treatment modalities (wearables, auto-injectors, etc.).

    Consumers like products with shock value, or at least novelty. This is something we’ve known within marketing for decades. And just when you thought everything had been tried, a new era of products with cheeky sayings has been basking in incredible success for several years now. It’s as if a product that ‘talks’ to you as the consumer is a cross-industry winning lottery ticket for sales revenue.

    This should remind us again that consumers are embarrassingly predictable and suggestible. Consumerism and fashion trends also work where the punchline isn’t explicitly obvious. So there are indeed Tesla vehicle models S, 3, X. The “3” was chosen in lieu of “E” in an attempt at a clever lexicographical effect; entrepreneurs don’t need to be necessarily smart, they just need to reliably display sociopathic traits.*

    Drugs as fashion
    How does this influences human health across great swaths of the population? Let’s look at drugs as fashion. There’s a certain fashion associated with which drugs are explored and which conditions receive preferential treatment. Typically when a new mechanism of action is discovered, or a particular disease receives outsized public attention, that drives investigational resources down particular—and not random or averaged—paths. So please get the idea out of your mind that the most-needed therapies get the most attention or that any treatment has an equal chance of being pioneered. It’s just not true.

    In this way, it’s entirely possible that social media campaigns and diseases that receive outsized levels of attention—perhaps because of a vocal ambassador or whatever—can drive resources away from the most debilitating medical conditions. Remember, those who pioneer causes are doing so agnostically of all other competing causes. So, by example, if we could create a prioritization matrix of all diseases and disorders measuring multivariate factors like prevalence, incidence, impact on daily function, pain, and so on, we would have a rational list of where to assign resources to do the most good—on average. Because this is never how social causes are approached, dollars that are allocated to a particular cause are done so at the expense of other, probably more deserving, causes. There are some econometrics influences in the above argument and economics effects that create a bit of variance. For example, the total number of ‘social cause dollars’ is finite, and therefore every dollar put on cause “A” is not available for cause “B.” But there’s also a behavioral economics effect where simply seeing others behave in a ‘social-cause-conscious’ fashion will cause people to also donate more than they otherwise would have—thus opening up more available funding than would otherwise be there in a rational economics model.

    So whether it’s a new drug delivery method, a new mechanism of action or a new type of viral social marketing, these all have discrete and real impacts on consumerism, and by extension, future pipelines of therapies. Over time, groupings of self-similar categories of attributes form the cyclical basis of fashion. Just like if you watch a movie from 10, 20, 30, 40 years ago, you can detect “fashionicity”—the property of displaying a recognizable pattern of fashion. Now think about this. When you look at blocks of time in the approval and use of drug treatments, and all medical interventions, for that matter, there are periods of time—marked periodicity—where self-similar categories emerge with competitors (e.g., SSRI-class antidepressants, cholesterol statins, etc.). These miniature periods of drug industry fashion bring with them dramatic potential help to patients who would be served by them. They also are harbingers of lost opportunity for other treatments that were marginalized to bring them to market.

    We might like to think that the ‘right’ drug developed for an emergent need would be uptaken by society (the patients) just by virtue of its existence. But it wouldn’t be to a large degree. And if by chance it was, this would be a clear and strong indicator against the need for sales and marketing folks in pharma. Having a good product, a good message marketed well, and a situation where they align with the capricious and irresolute perceived needs of the public is a sales trifecta.

    It’s clear that despite best intentions, consumerism is alive and well and has incredible influence on what new treatments go through the pipeline and eventually achieve market release. 

    *Incidentally, it should be noted that psychopathy isn’t a reliable medical diagnosis; so although you or your colleagues may toss this term around or hear it on a regular basis, a specifier for psychopathy only first appeared a handful of years ago in the Diagnostic and Statistical Manual of Mental Disorders (DSM) V. The World Health Organization and the American Psychiatric Association also disfavor the term.

    References
    1. Locwin, B. (2017). What’s in a Name? The Psychology of Drug Naming Conventions. Public speech presented at Future Pharma, Austin TX.
    2. DeMers, J. (2018). Do psychopaths make better entrepreneurs? Entrepreneur.

    Ben Locwin

    Ben Locwin, PhD, MBA, MS, MBB, is a widely-acclaimed author and international speaker on a variety of medical and healthcare topics. He was recently the Keynote for Contract Pharma’s 2018 Annual Conference and Expo.
    Related Searches
    • marketing
    • pipeline
    • patients
    • Drug Delivery
    Suggested For You
    Simplifying Recombinant Protein Production: Breaking Down the Corynex Protein Expression System Simplifying Recombinant Protein Production: Breaking Down the Corynex Protein Expression System
    A Government-run Drug Manufacturer? A Government-run Drug Manufacturer?
    Sartorius Launches Characterization Services for NBEs Sartorius Launches Characterization Services for NBEs
    Developing Translational Biologics for Brain Disorders Developing Translational Biologics for Brain Disorders
    AI in Pharma: Transforming Data into Drugs AI in Pharma: Transforming Data into Drugs
    Aileron, Pfizer in Clinical Collaboration Aileron, Pfizer in Clinical Collaboration
    The Great Diaspora of the Pharma Industry The Great Diaspora of the Pharma Industry
    “Clinically Speaking” “Clinically Speaking”
    Alcami Collaborates with Medicines Development for Global Health Alcami Collaborates with Medicines Development for Global Health
    No, Your Neighbors and Facebook Friends Don’t Know Anything About Health and Wellness No, Your Neighbors and Facebook Friends Don’t Know Anything About Health and Wellness
    Marrying Suppliers & Sponsors! Marrying Suppliers & Sponsors!
    HPAPI Equipment Advances HPAPI Equipment Advances
    Catalent Invests $7.3M at Aprilia, Italy Facility Catalent Invests $7.3M at Aprilia, Italy Facility
    Contracting And Outsourcing Agenda Contracting And Outsourcing Agenda
    CEPI, Emergent and Profectus Enter Vaccine Mfg. pact CEPI, Emergent and Profectus Enter Vaccine Mfg. pact

    Related Columns

    • Analytical Services | Laboratory Testing
      The Great Diaspora of the Pharma Industry

      The Great Diaspora of the Pharma Industry

      Or, good things come in small(er) packages
      Emil W. Ciurczak, DoraMaxx Consulting 11.14.18

    • “Clinically Speaking”

      “Clinically Speaking”

      Let’s get back to what it means to do things “clinically”
      Ben Locwin 11.14.18

    • Analytical Services | Laboratory Testing
      Possibly Time for a New Paradigm

      Possibly Time for a New Paradigm

      Or, why the chicken should cross the road
      Emil W. Ciurczak, DoraMaxx Consulting 10.10.18


    • No, Your Neighbors and Facebook Friends Don’t Know Anything About Health and Wellness

      No, Your Neighbors and Facebook Friends Don’t Know Anything About Health and Wellness

      And by the way, get your flu shot
      Ben Locwin 10.10.18

    • An “All-You-Can-Eat” Buffet for Excellence

      An “All-You-Can-Eat” Buffet for Excellence

      Or, touching on almost all editorial subjects for the month
      Emil W. Ciurczak, DoraMaxx Consulting 09.11.18

    • Pharma Future

      Pharma Future

      Where are we now? What’s next?
      Ben Locwin 09.11.18


    • CDMOs and Drug Shortages

      CDMOs and Drug Shortages

      A new proposal helps create a manufacturing backstop
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 09.11.18

    • Who is Responsible for Manufacturing Technology Innovation?

      Who is Responsible for Manufacturing Technology Innovation?

      Pharma’s future lies in putting innovations in the hands of innovators, not the regulators
      Girish Malhotra, Contributing Editor 09.11.18

    • Biopharmaceuticals Outsourcing Slows

      Biopharmaceuticals Outsourcing Slows

      Manufacturers are shifting focus
      Eric S. Langer, BioPlan Associates 09.11.18


    • The Right To Try

      The Right To Try

      A slippery slope that represents the complexity of being human
      Ben Locwin 07.20.18

    • Analytical Services | Laboratory Testing
      The Times, They Are a-Changin’

      The Times, They Are a-Changin’

      For contract organizations and generics, for sure
      Emil W. Ciurczak, DoraMaxx Consulting 07.20.18

    • Analytical Services | Bioanalytical Services | Laboratory Testing
      The Final Frontier

      The Final Frontier

      A look at contract bioprocessing and PAT/QbD
      Emil W. Ciurczak, DoraMaxx Consulting 06.12.18

    • Information Technology
      Putting Data Integrity in Quality Agreements

      Putting Data Integrity in Quality Agreements

      With growing regulatory scrutiny, sponsors are focusing more on data integrity in supplier quality agreements.
      Robert Marohn, ClinLogic, LLC 06.12.18

    • Regulatory Affairs
      India raises bar for clinical trial oversight

      India raises bar for clinical trial oversight

      New guidelines to bolster institutional ethical committees
      S. Harachand, Contributing Editor 05.08.18

    • The More Things Change, The More They… Change

      The More Things Change, The More They… Change

      A cautionary tale for BIO 2018
      Ben Locwin 05.08.18

    Breaking News
    • Valitacell, Solentim Form Biologics Collaboration
    • Executive Moves: Daiichi Sankyo Co.
    • Werum, B-EN-G Enter Partnership
    • Janssen, Morphic Ink Deal Worth up to $750M
    • Catalent Appoints Tech Ops SVP
    View Breaking News >
    CURRENT ISSUE

    January/February 2019

    • DCAT Week ’19
    • Temperature-Controlled Logistics
    • Reducing Pill Burden
    • Nasal Drug Delivery
    • AI in Pharma: Transforming Data into Drugs
    • Digitization: Pharma 4.0
    • Serialization Compliance: Understanding the Challenges
    • FDA & Data Integrity
    • Rising Demand for Lyophilized Products
    • Future Trends in the CDMO Space
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • privacy policy
    • term and condition
    • about us
    • contact us

    follow us

    Subscribe

    magazines

    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login